other material
confidence high
sentiment neutral
materiality 0.65
Avalo Therapeutics estimates $98M cash as of Dec 31, 2025 in preliminary update
Avalo Therapeutics, Inc.
- Preliminary cash, cash equivalents and short-term investments of ~$98M as of December 31, 2025.
- Estimate is unaudited and preliminary; actual year-end results may differ materially.
- Company also posted an updated investor presentation highlighting its IL-1β pipeline.
- Full financial results to be reported in the 2025 Form 10-K.